Press Release: Catamaran Bio : Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models
Read full article »
Catamaran Bio is a biotechnology company that researches and develops allogeneic CAR-NK cell therapies for the treatment of cancer.
Read more